A dangerous melamine substitution in nutritional products in China, the $75-million heist of drugs from Eli Lilly's Connecticut
warehouse, and 149 deaths in the US from contaminated heparin are all examples of headline-making news stories of pharmaceutical
supply-chain attacks. These types of threats are occurring with greater frequency, and concern for patient safety is escalating.
Counterfeit products, cargo theft, illegal diversion, and economically motivated adulteration are creating greater challenges
for Pfizer and other global pharmaceutical companies while putting patient safety at risk.
The World Health Organization (WHO) estimates that 10% of all pharmaceuticals in the global supply chain are counterfeit,
and that level may reach 70% in some developing countries (1). Although it is impossible to accurately quantify the extent
of the global problem, the impact of counterfeiting has been estimated to be as high as $200 billion per year (2). Other supplychain
security problems also are on the rise. From 2007 to 2009, for example, the rate of pharmaceutical cargo theft in the US jumped
Several business trends are contributing to the problem. Cost and pricing pressures, generic-drug competition, and challenges
with R&D productivity, coupled with the loss of exclusivity of key products—all are pushing pharmaceutical companies toward
more complex supply chains, increased levels of contract manufacturing, and more licensing agreements. These issues, along
with companies' efforts to expand into new and emerging markets, are providing ample opportunity for criminals to illegally
enter the supply chain.
We all realize that we operate in a global marketplace. The pharmaceutical industry's raw materials may originate in one part
of the world while products are manufactured in another. Packaging can occur in many markets, and products are transported
and sold globally. Supply-chain security is an international issue and a global health imperative.
To successfully address the problem, pharmaceutical companies, regulators, suppliers, law enforcement, and other supply-chain
partners must work closely and cooperatively together. Collaboration already is occurring through organizations such as Rx–360,
World Health Organization, the Pharmaceutical Security Institute, the Partnership for Safe Medicines, and Interpol to name
The pharmaceutical industry, consumers, and the public at large should realize that we are all in this together. Effective
global solutions are required to shore up the entire supply-chain security system because criminals will always attack the
weakest links to steal, divert, counterfeit, or adulterate drug products.
The main players in the supply chain—pharmaceutical companies and their external partners, trade groups, law enforcement,
government agencies, and industry consortiums—can influence change. Whether by working together or in part (i.e., as a group
proposing a strategy, by influencing another partner in the chain, by supporting an initiative, or by implementing a specific
requirement), we can, for example, increase global penalties for supply-chain crimes, increase public awareness of supply-chain
risks, share best practices, and work to develop harmonized global supply-chain solutions. We must embrace opportunities for
the industry and its stakeholders to work together to keep the pharmaceutical supply chain safe for millions of patients who
depend upon the products it provides to improve their lives. They expect safe and effective medicines, and it is the industry's
responsibility to deliver them.
Holistic approach to supply-chain security
External partnerships and cooperation are vital to keep the global supply of medicines safe, but pharmaceutical companies
also can do a great deal to maximize supply-chain security at the organizational level within their companies. The industry
can start by taking a holistic approach to supply-chain security from the procurement of raw materials through product delivery.
Risk-management principles and integrated layers of protection are important at each juncture of the supply-chain continuum.
Pharmaceutical companies need to understand and integrate the myriad internal organizations and activities that touch their
supply chains and collaborate to reach effective solutions.
The areas that make up the supply chain—including raw-materials procurement, manufacturing (internal manufacturing and through
external suppliers), transportation, warehousing, quality, distribution, and marketplace monitoring—must be aligned and work
together for maximum effectiveness.